A PHASE II TRIAL OF ERLOTINIB VERSUS PEMETREXED AS SECOND-LINE THERAPY IN TREATING PATIENTS WITH ADVANCED EGFR WILD-TYPE AND EGFR FISH-POSITIVE LUNG ADENOCARCINOMA

被引：0
作者：
Wang, Si-Yu [1 ]
Li, Ning [1 ]
Ou, Wei [1 ]
Zhang, Liang [1 ]
Zhang, Song-Liang [1 ]
机构：
[1] Sun Yat Sen Univ, Guangzhou, Guangdong, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2013年 / 8卷
关键词：
non-small cell lung cancer; second-line;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.10-028
引用
收藏
页码：S575 / S575
页数：1
相关论文
共 50 条
  • [41] An exploratory comparative analysis of tyrosine kinase inhibitors or docetaxel in second-line treatment of EGFR wild-type non-small-cell lung cancer: a retrospective real-world practice review at a single tertiary care centre
    Ma, K.
    Cohen, V.
    Kasymjanova, G.
    Small, D.
    Novac, K.
    Peterson, J.
    Levit, A.
    Agulnik, J.
    CURRENT ONCOLOGY, 2015, 22 (03) : E157 - E163
  • [42] Randomized phase II study of three doses of the integrin inhibitor cilengitide versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer
    Christian Manegold
    Johan Vansteenkiste
    Felipe Cardenal
    Wolfgang Schuette
    Penella J. Woll
    Ernst Ulsperger
    Anne Kerber
    Josef Eckmayr
    Joachim von Pawel
    Investigational New Drugs, 2013, 31 : 175 - 182
  • [43] A Phase II Trial of Gefitinib in Combination with Bevacizumab as First-Line Therapy for Advanced Non-Small Cell Lung Cancer with Activating EGFR Gene Mutations: The Okayama Lung Cancer Study Group Trial 1001
    Ichihara, Eiki
    Hotta, Katsuyuki
    Nogami, Naoyuki
    Kuyama, Shoichi
    Kishino, Daizo
    Fujii, Masanori
    Kozuki, Toshiyuki
    Tabata, Masahiro
    Harada, Daijiro
    Chikamori, Kenichi
    Aoe, Keisuke
    Ueoka, Hiroshi
    Hosokawa, Shinobu
    Bessho, Akihiro
    Hisamoto-Sato, Akiko
    Kubo, Toshio
    Oze, Isao
    Takigawa, Nagio
    Tanimoto, Mitsune
    Kiura, Katsuyuki
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (03) : 486 - 491
  • [44] Randomized phase II study of three doses of the integrin inhibitor cilengitide versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer
    Manegold, Christian
    Vansteenkiste, Johan
    Cardenal, Felipe
    Schuette, Wolfgang
    Woll, Penella J.
    Ulsperger, Ernst
    Kerber, Anne
    Eckmayr, Josef
    von Pawel, Joachim
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (01) : 175 - 182
  • [45] A multicenter phase II study of sorafenib monotherapy in clinically selected patients with advanced lung adenocarcinoma after failure of EGFR-TKI therapy (Chinese Thoracic Oncology Group, CTONG 0805)
    Zhou, Qing
    Zhou, Cai-cun
    Chen, Gong-yan
    Cheng, Ying
    Huang, Cheng
    Zhang, Li
    Xu, Chong-rui
    Li, Ai-wu
    Yan, Hong-hong
    Su, Jian
    Zhang, Xu-chao
    Yang, Jin-ji
    Wu, Yi-long
    LUNG CANCER, 2014, 83 (03) : 369 - 373
  • [46] Efficacy and Safety of Docetaxel and Sodium Cantharidinate Combination vs. Either Agent Alone as Second-Line Treatment for Advanced/Metastatic NSCLC With Wild-Type or Unknown EGFR Status: An Open-Label, Randomized Controlled, Prospective, Multi-Center Phase III Trial (Cando-L1)
    Wu, Lin
    Deng, Chao
    Zhang, Hui
    Weng, Jie
    Wu, Youhua
    Zeng, Shan
    Tang, Tiegang
    Cao, Peiguo
    Qiu, Bo
    Zhang, Li
    Duan, Huaxin
    Zhang, Bing
    Zhang, Dong
    Zhang, Taotao
    Hu, Chunhong
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [47] Osimertinib for patients with poor performance status and EGFR T790M mutation-positive advanced non-small cell lung cancer: a phase II clinical trial
    Kazuhisa Nakashima
    Yuichi Ozawa
    Haruko Daga
    Hisao Imai
    Motohiro Tamiya
    Takaaki Tokito
    Takahisa Kawamura
    Hiroaki Akamatsu
    Yuko Tsuboguchi
    Toshiaki Takahashi
    Nobuyuki Yamamoto
    Keita Mori
    Haruyasu Murakami
    Investigational New Drugs, 2020, 38 : 1854 - 1861
  • [48] Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer With Progressive Disease on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy: A California Cancer Consortium Phase II Trial (NCI 9303)
    Reckamp, Karen L.
    Frankel, Paul H.
    Ruel, Nora
    Macke, Philip C.
    Gitlitz, Barbara J.
    Li, Tianhong
    Koczywas, Marianna
    Gadgeel, Shirish M.
    Cristea, Mihaela C.
    Belani, Chandra P.
    Newman, Edward M.
    Gandara, David R.
    Lara, Primo N., Jr.
    FRONTIERS IN ONCOLOGY, 2019, 9
  • [49] Osimertinib for patients with poor performance status and EGFR T790M mutation-positive advanced non-small cell lung cancer: a phase II clinical trial
    Nakashima, Kazuhisa
    Ozawa, Yuichi
    Daga, Haruko
    Imai, Hisao
    Tamiya, Motohiro
    Tokito, Takaaki
    Kawamura, Takahisa
    Akamatsu, Hiroaki
    Tsuboguchi, Yuko
    Takahashi, Toshiaki
    Yamamoto, Nobuyuki
    Mori, Keita
    Murakami, Haruyasu
    INVESTIGATIONAL NEW DRUGS, 2020, 38 (06) : 1854 - 1861
  • [50] TREATMENT RATIONALE AND STUDY DESIGN FOR AN OPEN-LABEL RANDOMIZED PHASE II TRIAL OF GEMCITABINE AND CISPLATIN WITH OR WITHOUT BEVACIZUMAB IN EGFR WILD-TYPE NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER
    Li, Juan
    Yu, Ping
    Liu, Bin
    Yang, Ye
    Liu, Xiaoqin
    Wen, Yan
    Tan, Xiaohui
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S590 - S590
12345